|
| A) | Stroke | ||
| B) | Suicide | ||
| C) | Alzheimer disease | ||
| D) | Pneumonia/influenza |
| A) | Diabetes | ||
| B) | Homicide | ||
| C) | Chronic liver disease | ||
| D) | Cerebrovascular diseases |
TEN LEADING CAUSES OF DEATH FOR MEN ACCORDING TO RACE/ETHNICITY, 2018
| Leading Causes of Death | Mortality Rate and Rank | |||||
|---|---|---|---|---|---|---|
| All Men | White | Black/African American | Hispanic/Latino | Asian/Pacific Islander | American Indian/Alaskan Native | |
| Cardiovascular diseases | 24.4% (1) | 24.8% (1) | 24.1% (1) | 20.2% (1) | 23.1% (2) | 18.9% (1) |
| Cancer | 22.2% (2) | 22.2% (2) | 19.7% (2) | 19.4% (2) | 24.7% (1) | 15.9% (2) |
| Unintentional injuries | 6.8% (3) | 6.9% (3) | — | 11.3% (3) | 5.3% (4) | 13.7% (3) |
| Chronic lower respiratory diseases | 5.3% (4) | 5.8% (4) | 3.2% (7) | 3.3% (6) | 3.2% (6) | 3.6% (7) |
| Stroke | 4.2% (5) | 4.1% (5) | 5.0% (4) | 4.7% (4) | 6.7% (3) | 2.9% (8) |
| Diabetes mellitus | 3.1% (6) | 2.9% (6) | 4.4% (6) | 4.2% (5) | 4.2% (5) | 5.7% (5) |
| Suicide | 2.5% (7) | 2.7% (8) | — | 3.1% (8) | 2.6% (8) | 4.2% (6) |
| Alzheimer disease | 2.5% (8) | 2.9% (7) | 7.9% (3) | 2.3% (9) | 2.3% (9) | — |
| Influenza and pneumonia | 2.0% (9) | 2.0% (9) | 1.7% (10) | 3.2% (7) | 3.2% (7) | 2.2% (10) |
| Chronic liver disease | 1.9% (10) | 1.7% (10) | — | 4.1% (6) | — | 6.1% (4) |
| Assault (homicide) | — | — | 4.5% (5) | 2.2% (10) | — | 2.3% (9) |
| Kidney disease | — | — | 2.7% (8) | — | 2.0% (10) | — |
| Septicemia | — | — | 1.7% (9) | — | — | — |
| A) | lung cancer. | ||
| B) | liver cancer. | ||
| C) | prostate cancer. | ||
| D) | pancreatic cancer. |
| A) | The highest rate is found among White men. | ||
| B) | The number of occupational deaths is higher for men than women. | ||
| C) | The number of deaths related to motor vehicle accidents is lower for men than women. | ||
| D) | The number of deaths caused by unintentional injury among men in the United States is lower than the median for every other country around the world. |
Men's predilection for risky behavior is reflected in the high rate of unintentional injury, which accounts for 7.4% of deaths among men (compared with 4.3% for women) [7,8]. There is wide variation in this rate across race/ethnicity, with much higher rates among American Indian/Alaska Native men (13.7%) and Hispanic/Latino men (11.3%) [11]. The trend of more fatal unintentional injuries among men is evident in countries around the world; an analysis of accidental deaths among men and women in 36 countries showed higher rates for men [2]. Across all age-groups, the rates were higher in the United States than the median rate for all countries. Accidental deaths are related primarily to motor vehicle injuries, violence, and occupation, and the rates in all categories are higher for men than for women. The rate of death related to motor vehicle injuries for men is slightly higher than for women (16.0 vs. 6.3 per 100,000), and the percentage of fatal unintentional firearm-related injuries deaths occur overwhelmingly more often among men (82.7%) than women (17.3%) [25]. Similarly, fatal occupational injuries occur predominantly in men (57% vs. 6%) [26].
| A) | Men are more likely than women to have screening tests. | ||
| B) | Most men seek care as soon as possible when they are sick. | ||
| C) | Men are more likely than women to lack a usual source of health care. | ||
| D) | Men are forthcoming about symptoms with their healthcare providers. |
Help- and information-seeking behavior related to male gender identity is another factor that affects men's health. In general, men are reluctant to seek health care or talk about their health because they see such help-seeking as a sign of weakness or vulnerability and a threat to their masculinity [4,35,36]. These reports are substantiated by data on utilization of healthcare resources, which indicate that men have fewer office visits to doctors or other health care professional than women; in 2018, 23.9% of men had no office visits, compared with 12.5% of women [37]. In addition, men are more likely to lack a usual source of health care (18.6% vs. 10.7%) [37]. Men have reported several reasons for not having a usual source of care, and the reasons vary among racial/ethnic populations [39]. The reason given most often is that they are seldom or never sick, and this may be related to men's perceptions of invulnerability [39,40]. Other reasons given include not finding time and not being able to take time away from work [38]. Cultural values, such as machismo, lead many Hispanic men to avoid health care until there is no other choice [40]. This may contribute to the low rate of healthcare use among Hispanic men, which is the lowest across racial/ethnic populations [40]. Other reasons for the low use of healthcare services among Hispanic men are lack of health insurance, low understanding of the healthcare system, fear of poor functional outcomes, and a low perception of the quality of the patient-clinician interaction [40]. In the Black population, men have reported to avoid healthcare services because of fears and concerns about their negative health behaviors and history [41].
| A) | the most common type of prostatitis. | ||
| B) | the easiest type of prostatitis to diagnose. | ||
| C) | more common in men older than 40 years of age. | ||
| D) | the type that causes the most significant impact on the quality of life. |
Both acute and chronic bacterial prostatitis occur in approximately 5% to 10% of men with symptoms related to prostatitis. Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is the most common type, occurring in approximately 90% of symptomatic men [60]. These three types of prostatitis are addressed here; asymptomatic inflammatory prostatitis is an incidental finding during evaluation of another genitourinary condition such as prostate cancer or infertility [61].
It has been estimated that prostatitis accounts for approximately 2 million outpatient visits per year in the United States, with a direct cost of care of nearly $4,000 per patient per year [61]. The condition can have a substantial impact on the quality of life, causing pain and sexual dysfunction, as well as decreased libido and erectile and ejaculatory dysfunction [62,63].
Chronic prostatitis/chronic pelvic pain syndrome has the greatest impact on the quality of life of all types of prostatitis. Studies have found that the effect of chronic pelvic pain syndrome on the quality of life is similar to that of angina, congestive heart failure, diabetes mellitus, and Crohn disease [61]. Symptoms fluctuate over time; one study showed that 43% of men had symptoms within 11 months of follow-up, and another showed that 31% of men had moderate or marked improvement during two years of follow-up [64,65]. Chronic prostatitis/chronic pelvic pain syndrome also causes patient anxiety at the initial visit. Most men with symptoms worry that they have an infection (71%) or cancer (68%), and concerns at one-year follow-up have included worsening symptoms without treatment, cancer, infection, and need for surgery [65]. These concerns have led to an increased number of physician visits [65].
The prevalence of prostatitis has been reported to be approximately 8%, ranging from about 2% to 10% [66]. In patients younger than 35 years of age, the most common variant of the syndrome is acute bacterial prostatitis. Among older patients, nonbacterial prostatitis (NIH types II and IV) is the most common [67]. The results of studies have suggested that the symptoms of prostatitis increase the risk for BPH, lower urinary tract symptoms, and prostate cancer [66].
The cause of acute and chronic bacterial prostatitis is usually lower urinary tract infection with gram-negative organisms, most notably Escherichia coli [60,61]. Most men with prostatitis, however, have no evidence of urinary tract infection [61]. Other causes may include a primary voiding dysfunction problem; presence of Chlamydia trachomatis, Ureaplasma species, or Trichomonas vaginalis; uncommon organisms (e.g., Mycobacterium tuberculosis); HIV; cytomegalovirus; and inflammatory conditions (e.g., sarcoidosis) [67].
The risk factors for prostatitis have not been clearly defined. In a study of 463 men with chronic prostatitis/chronic pelvic pain and 121 asymptomatic age-matched controls, the lifetime prevalence of several self-reported medical conditions were significantly greater among men with prostatitis, specifically neurologic disease (41% vs. 14%); hematopoietic, lymphatic, or infectious disease (41% vs. 20%); psychiatric conditions (29% vs. 11%); nonspecific urethritis (12% vs. 4%); and cardiovascular disease (11% vs. 2%) [68]. The authors of that study noted that more research is needed to determine if such conditions contribute to the pathogenesis of chronic prostatitis/chronic pelvic pain. A history of STIs has been noted to be associated with an increased risk for prostatitis symptoms [66].
Several other urogenital conditions should be considered in the differential diagnosis of prostatitis, including BPH, cystitis, erectile dysfunction, prostate cancer, STI, and urolithiasis [69,70,353]. Of the four types of prostatitis, acute bacterial prostatitis is the easiest to diagnose and treat. Patients with acute prostatitis present with irritative symptoms (dysuria, urinary frequency, and urgency), and obstructive voiding symptoms (hesitancy, incomplete voiding, straining to urinate); the syndrome may also include signs of systemic infection, such as chills and fever [70,353]. Pain most commonly occurs in the prostate/perineum and scrotum and/or testes; pain referred to the penis or lower back also occurs [70]. Urine samples should be cultured to determine the causative micro-organism.
| A) | the evaluation should not include a urinalysis and urine culture. | ||
| B) | the Meares-Stamey test is helpful for diagnosing chronic pelvic pain syndrome. | ||
| C) | a history of recurrent urinary tract infections is indicative of acute bacterial prostatitis. | ||
| D) | the National Institute of Health (NIH) Chronic Prostatitis Symptom Index should be completed to obtain a baseline for the severity of symptoms. |
Chronic bacterial prostatitis is distinguished from acute disease by time, being defined by persistence of symptoms for at least three months, and systemic symptoms are usually absent [58,70]. The condition should be suspected when the patient's history includes recurrent urinary tract infections, usually with the same bacterial strain [61]. The patient should complete an NIH Chronic Prostatitis Symptom Index to obtain a baseline score for the severity of symptoms [59]. This index includes questions related to three domains—pain, urinary symptoms, and quality-of-life impact—and has been shown to be a valid, reliable tool for measuring prostatitis symptoms [70,71]. Computed tomography (CT) can determine if there are structural or functional abnormalities of the urinary tract [60,61].
The diagnostic evaluation for acute or chronic bacterial prostatitis includes a urinalysis and urine culture [61,70]. When acute prostatitis is suspected, digital rectal exam should be performed gently so as not to precipitate bacteremia and sepsis. The prostate will usually be enlarged, boggy, and tender, though absence of tenderness on initial examination does not exclude the diagnosis of prostatitis. There are no standardized criteria for the diagnosis of chronic prostatitis/chronic pelvic pain syndrome [61,69]. The Meares-Stamey four-glass test was developed in the late 1960s to screen for prostatitis; the test involves collecting urine samples before and after prostatic massage, as well as collecting prostatic fluid during the massage [72]. Cultures are done on the specimens, and the presence of micro-organisms in the prostatic fluid indicates chronic prostatitis [61,72]. The accuracy and reliability of the test has not been established, and studies have shown that the test is not used often, even by urologists [61,69]. There is also a two-glass version of the test that has correlated well with the four-glass version, but that, too, is not often used [61]. The Meares-Stamey test is not helpful for diagnosing chronic pelvic pain syndrome. Men who have substantial lower urinary tract symptoms and pelvic pain may be candidates for urodynamic evaluation, as voiding dysfunction is common in such cases [61].
| A) | Trimethoprim should not be used. | ||
| B) | Pregabalin has improved symptoms. | ||
| C) | An alpha-blocker alone has provided more benefit than an alpha-blocker plus antibiotic. | ||
| D) | Fluoroquinolones have improved symptoms even when no bacterial cause has been identified. |
For chronic bacterial prostatitis, the choice of antibiotic depends on the sensitivity of the micro-organism, and the antibiotic should be one that penetrates the prostate [61]. The typical first-line treatment is a four- to six-week course of a fluoroquinolone, and treatment is usually more effective if begun soon after symptoms begin [61,70,73,74]. Trimethoprim-sulfamethoxazole may also be considered [70].
Treatment for chronic prostatitis/chronic pelvic pain syndrome is complex; evidence on the effect of traditional treatment options has been conflicting, and treatment options are often not effective in managing symptoms. The most commonly studied pharmacologic options are antibiotics, alpha-blockers, anti-inflammatory agents, steroid inhibitors, and muscle relaxants, and often, a combination of these agents provides the most effective management [74]. Antibiotics, particularly fluoroquinolones, have improved symptoms, even in some patients in whom a bacterial cause has not been identified [74]. Studies have shown that an antibiotic and an alpha-blocker is more effective than an antibiotic alone [70]. A meta-analysis showed that alpha-blockers, antibiotics, and a combination of the two all significantly improve symptoms (according to scores on the NIH Chronic Prostatitis Symptom Index), with the combination providing the greatest benefit [75]. However, another meta-analysis showed that these same agents—alone and in combination—were not associated with a statistically or clinically significant decrease in symptom scores [76]. The combination of an alpha-blocker (doxazosin) with an anti-inflammatory agent (ibuprofen) and a muscle relaxant (thiocolchicoside) led to a statistically and clinically significant reduction in the total score on the NIH Chronic Prostatitis Symptom Index in one systematic review; according to the findings of another systematic review, the three-agent combination was not superior to monotherapy [74,76]. Researchers have cautioned that publication bias may cause overestimation of the beneficial effects of alpha-blockers and that the placebo effect has been significant in many studies [75,76]. Addressing a hypothesis that the pain related to chronic prostatitis may have a neuropathic origin, pregabalin has been evaluated as a management strategy, but a systematic review found that the drug did not improve symptoms and caused side effects in a large percentage of men [77].
| A) | Asian race. | ||
| B) | increased age. | ||
| C) | a genetic mutation | ||
| D) | family history of cancer. |
The prevalence of BPH increases with age, from approximately 8% of men 31 to 40 years of age to approximately 90% of men in their 80s [80,81]. Risk factors identified in one study included increased age, prostatic volume, and peak urinary flow rate [82]. Other factors, including some that are modifiable, include obesity, diet, dyslipidemia, hypertension, alcohol use, and smoking [83]. The relative risk for BPH (and common comorbidities) may be higher for Black and Hispanic men than for White men and is thought to be related in part to genetic differences based on race/ethnicity; however, observational studies have produced variable results [81,84].
| A) | Silodosin | ||
| B) | Dutasteride | ||
| C) | Watchful waiting | ||
| D) | Transurethral needle ablation |
The AUA guideline recommends watchful waiting as the preferred approach for men who have mild symptoms (a score of less than 8 on the AUA Symptom Index) [78]. This approach may also be taken for men with moderate-to-severe symptoms (score of 8 or more) who are not bothered by the symptoms and have no complications [87]. Watchful waiting should include yearly evaluations similar to the initial one [78]. Lifestyle changes and behavioral interventions are considered reasonable first-line treatments for all patients. Symptoms may be reduced by avoiding decongestants and antihistamines, decreasing fluid intake (and avoiding caffeine and alcohol) prior to bedtime, and increasing physical activity and weight loss [78].
| A) | Black race | ||
| B) | Advanced age | ||
| C) | Family history | ||
| D) | Sexual activity |
The known risk factors for prostate cancer are advanced age, Black race, and a family history of the disease (especially when diagnosed at a younger age) [16,97]. The risk for prostate cancer may also be increased for men with symptoms of prostatitis [66].
| A) | increased time to onset of disease. | ||
| B) | decreased risk for all-cause mortality. | ||
| C) | increased risk for high-grade prostate cancer. | ||
| D) | increased risk for prostate cancer-specific mortality. |
Several studies have been undertaken to determine the efficacy of chemoprevention agents and dietary supplements to reduce the risk of prostate cancer. The chemoprevention agents evaluated belong to the class of 5-alpha reductase inhibitors, a class of drugs approved for the treatment of BPH. One drug in this class, finasteride, was evaluated in the first large-scale chemoprevention study, the Prostate Cancer Prevention Trial (PCPT), a seven-year study involving nearly 19,000 men 55 years of age or older. In that study, finasteride significantly reduced the prevalence of prostate cancer (18% vs. 24% for the placebo group) [98]. Dutasteride was shown to decrease the risk of prostate cancer in the REDUCE trial, and extended follow-up indicated a low rate of new prostate cancer diagnoses [99,100]. The initial results of the PCPT and REDUCE trials led the American Society of Clinical Oncology (ASCO) and the AUA to develop a joint guideline recommending finasteride and dutasteride for the prevention of prostate cancer [90]. However, reanalysis of the results of the trials showed that the risk for high-grade prostate cancer was increased and the reduction in prostate cancer risk was seen primarily for less fatal subtypes of prostate cancer that are often not treated [100,101]. In 2011, the FDA decided against approving the two drugs for the prevention of prostate cancer, noting that the risk-benefit profile is not favorable for chemoprevention [91,101,102]. As stated earlier, the FDA revised the labels of all 5-alpha reductase inhibitors to note the increased risk of higher-grade prostate cancer associated with the drugs [92]. The ASCO/AUA guideline was withdrawn, and experts have called for more research to determine whether 5-alpha reductase inhibitors have a role in the prevention of prostate cancer [101,102,103].
| A) | lower mortality rates. | ||
| B) | decreased need for biopsy. | ||
| C) | diagnosis at an earlier stage. | ||
| D) | higher prevalence of definitive disease. |
There is no question that available screening methods and enhanced awareness has led to an increased number of men in whom prostate cancer is diagnosed at an earlier stage. The primary benefit of screening is a lower stage and grade of cancer at the time of diagnosis, and the high rate of localized disease at the time of diagnosis (92% to 96%) reflects, in part, the increased number of cancers that are detected earlier through screening [102,108,109]. Despite this benefit, an effect of screening on mortality has not been clearly demonstrated. After 13 years of follow-up in the National Cancer Institute's Prostate, Lung, Colon, and Ovary (PLCO) trial, there was no benefit of annual screening on mortality [110]. A meta-analysis (five randomized controlled trials) similarly demonstrated no effect of screening on prostate cancer-specific or overall mortality [111]. However, data from the European Randomized Study of Screening for Prostate Cancer demonstrated that screening reduced the risk for prostate cancer death by 7% to 9% per year [112].
| A) | A PSA level of 1.0 ng/mL is a recommended threshold for biopsy. | ||
| B) | Free PSA levels are helpful for men with PSA levels greater than 10 ng/mL. | ||
| C) | PSA density offers significant benefits compared with other PSA derivatives. | ||
| D) | PSA velocity is helpful for longitudinal monitoring of men younger than 50 years. |
PSA density is the result of dividing the PSA level by the volume of the prostate, as measured by transrectal ultrasonography, and a higher result suggests a greater likelihood of prostate cancer [97]. Greater PSA density has correlated with the presence of prostate cancer, as well as with the pathologic stage of the tumor and its aggressiveness and progression after treatment [124]. The use of PSA density has been limited by the lack of precision of total PSA, of measurement of prostate volume, and of the need to carry out transrectal ultrasonography [97]. In addition, PSA density does not offer much benefit compared with other PSA derivatives [97]. PSA velocity is the rate at which a PSA level increases over a period of time, and it has been most helpful for longitudinal monitoring of men younger than 50 years of age who have normal PSA levels and no prostate enlargement [97]. A high PSA velocity alone should not prompt biopsy but instead, aid in decision making [97]. The test is not useful for men with PSA values greater than 10 ng/mL [97]. The ratio of complexed PSA to total PSA provides information comparable to the ratio of free to total PSA, and the use of complexed PSA has been approved as a detection aid (in conjunction with DRE) for men 50 years of age or older; however, the test is not widely used in practice [97].
| A) | odds ratio. | ||
| B) | absolute risk reduction. | ||
| C) | number needed to treat. | ||
| D) | the probability of a decrease in mortality. |
Each treatment option is associated with benefits and harms, and clinicians should discuss each option in detail and provide educational resources and decision aids [129,130,131]. To gain a true understanding of a patient's preferences, treatment options should be discussed only after the patient has described his preferences [132]. Clinicians should carefully assess their patients' understanding of treatment options; studies of underserved men have shown low comprehension of common terms used in prostate cancer treatment discussions [133,134]. Attention should also be paid to how to best communicate risk. A study has shown that such terms as "number needed to treat," "odds ratio," and "relative risk reduction" were confusing to men [135]. In that study, men best understood information when it was presented as an absolute risk reduction and in a positive context; men preferred that treatment options be discussed in terms of the probability of an increase in survival (rather than a decrease in mortality) and that the discussion include the impact of treatment on patient-centered quality-of-life outcomes [135].
| A) | Radiation therapy | ||
| B) | Active surveillance | ||
| C) | Radical prostatectomy | ||
| D) | Androgen deprivation therapy |
The NCCN Panel recommends active surveillance for all men with very-low-risk prostate cancer and a life expectancy of less than 20 years and believes that surveillance should be considered for men with very-low-risk prostate cancer and a life expectancy of 20 years or more [126]. In addition, the Panel recommends active surveillance for all men with low- and favorable intermediate-risk prostate cancer and a life expectancy of less than 20 years and believes that it should be considered for men with low- and favorable intermediate-risk and a life expectancy of 10 years or more [126]. With active surveillance, recommended monitoring is measurement of a PSA level no more than every 6 months, unless clinically indicated, and physical exam with DRE every 12 months [126]. An increase in PSA should prompt re-testing as transient PSA elevations are common; serial PSA increases, new DRE abnormalities, or other concerns for clinical progression should prompt re-evaluation with prostate MRI and possible prostate biopsy [126,358].
| A) | brachytherapy. | ||
| B) | chemotherapy. | ||
| C) | radical prostatectomy. | ||
| D) | androgen deprivation therapy. |
Both NCCN and ASCO recommend ADT as initial treatment for metastatic prostate cancer [126,155]. Researchers have evaluated the timing of ADT—early (before symptoms occur) or delayed—and early therapy has provided no overall survival benefit and only a modest decrease in risk for prostate cancer-specific mortality; because of this, the ASCO guideline does not make a recommendation for early ADT [155]. Several studies have demonstrated that intermittent ADT is as effective as continuous ADT for metastatic or locally advanced disease, with better quality of life and fewer side effects [156,157,158].
| A) | Insidious onset of pain | ||
| B) | Absence of the cremasteric reflex | ||
| C) | Increased blood flow on Doppler ultrasonography | ||
| D) | All of the above |
The most common misdiagnosis of testicular torsion is epididymitis [164,167]. The first step should be to determine the onset of pain, as testicular torsion is associated with pain of sudden onset; in contrast, the onset of pain is insidious in epididymitis and other conditions [164,165]. The physical examination also plays an important role in distinguishing testicular torsion from epididymitis. A key distinction is the absence of the cremasteric reflex in testicular torsion, which has been found to have a sensitivity of at least 99% in two studies of boys [167,168]. To elicit this reflex, the medial thigh is stroked or pinched, which causes contraction of the cremaster muscle and elevation of the testis. If the testicle moves at least 0.5 cm, the reflex is positive [164]. Other distinguishing features include the area of tenderness, appearance of the scrotum, and testicular lie (Table 9) [164,165,167,168].
| A) | urinary retention. | ||
| B) | unilateral tenderness. | ||
| C) | pain with extended standing. | ||
| D) | sudden onset of pain in both testicles. |
Men with acute epididymitis usually present with unilateral pain and tenderness in the testicle [173]. Additional symptoms include dysuria, urinary frequency or urgency, and symptoms related to the source of infection (e.g., fever, chills, or pain). Urinalysis and urine culture should be done to determine the presence of infection [175,176].
| A) | more common in infertile men. | ||
| B) | a source of substantial unilateral pain. | ||
| C) | more pronounced when the patient is recumbent. | ||
| D) | associated with a hardness of the testes in older men. |
A varicocele is a dilated, tortuous inflammation of the veins of the spermatic cord above the testicle. A prevailing thought has been that the superior mesenteric artery compresses the left renal vein over the aorta, also known as the "nutcracker effect" [178]. This theory has been confirmed by studies that have shown that varicoceles are less common in obese men [178,179]. It has also been suggested that the condition is caused by damage to the contractile mechanism of the smooth muscle organization of spermatic veins [180]. As a result of anatomic differences, the condition is more common in the left testicle, but advances in imaging have led to reports of high rates of bilaterality [181]. Varicocele can cause discomfort in the scrotal area, but usually the condition is asymptomatic [165].
The frequency of varicocele among adolescents and young adults is approximately 15% to 20%, and the rate is higher among men who have some level of infertility, with reports of 77% and 81% in some studies [181,182]. A study of older men (mean age: 60.7 years) demonstrated a prevalence of 42% [183].
Varicoceles vary in size, and large ones can be identified through physical examination alone. Varicoceles can have an adverse effect on spermatogenesis, and infertility has been associated with varicoceles that can be palpated [182]. The most significant finding is a feeling of a "bag of worms" when the scrotum is palpated [165,182]. The varicocele may disappear or be substantially reduced when the patient is recumbent [182]. Smaller varicoceles can be detected by asking the patient to perform the Valsalva maneuver in the standing position [182]. In older men (at least 60 years of age), varicoceles have been associated with significantly smaller and soft testes [183]. Color Doppler ultrasonography is the diagnostic procedure of choice when the findings of the clinical examination are inconclusive [182].
| A) | cryptorchidism. | ||
| B) | testicular dysgenesis. | ||
| C) | family history of cancer. | ||
| D) | history of cancer in the contralateral testicle. |
Among the several risk factors for testicular cancer, the primary one is cryptorchidism, which can increase the risk 11-fold [177]. Other risk factors include a family history of the disease, testicular dysgenesis, and Klinefelter syndrome [177]. A history of cancer in one testicle confers an increased risk (2% to 5%) of cancer in the contralateral testicle over the 25 years following diagnosis [192].
| A) | AFP level. | ||
| B) | LDH level. | ||
| C) | beta-hCG level. | ||
| D) | beta-hCG level and a normal AFP level. |
According to the NCCN guideline for the treatment of testicular cancer, testicular ultrasonography is optional if a diagnosis is obvious from the physical examination, but the guideline notes that this diagnostic test is usually done to define the lesion [177]. Both the NCCN and ASCO recommend measuring serum levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase (LDH) to help determine if the testicular mass is a germ cell tumor and, if so, whether it is a seminoma or a nonseminoma [177,194]. A nonseminoma is associated with an elevated AFP level; in contrast, an elevated level of beta-hCG, with a normal AFP level, usually indicates a seminoma [177]. Additional evaluation should include a chest x-ray and CT of the abdomen and pelvis to determine if lymph nodes are involved [177]. If metastatic disease is suspected, further imaging studies, such as bone scan, magnetic resonance imaging, or positron emission tomography, may be necessary. Open biopsy is not usually performed [177].
| A) | hearing loss. | ||
| B) | oligospermia. | ||
| C) | erectile dysfunction. | ||
| D) | secondary leukemias. |
The follow-up evaluation plays an important role in assessing for the long-term effects of treatment. The primary effect of chemotherapy is oligospermia, but sperm production can be recovered [195,196]. A population-based study found that 70% of testicular cancer survivors fathered children [197]. Secondary acute leukemias have been reported to develop after chemotherapy and radiation therapy, and other consequences of platinum-based chemotherapy include hearing deficits and impaired renal function [198,199]. Melanomas and cancers at many sites have been associated with radiation therapy, occurring 10 years or more after treatment [198]. Lastly, the risk of cardiac events has been increased for testicular cancer survivors who had been treated with radiation therapy and/or chemotherapy [200].
| A) | Lumpectomy is rarely performed. | ||
| B) | The BRCA2 mutation is found in most cases. | ||
| C) | Adjuvant hormone therapy has a limited role in treatment. | ||
| D) | Sentinel lymph node biopsy has not been found to be effective. |
BRCA2 mutation is found in approximately 4% to 16% of men with breast cancer [203].
A painless subareolar lump or swelling is the most common presenting symptom, occurring in approximately 85% of men with breast cancer [201,204]. Other common symptoms are nipple retraction, localized pain, or nipple ulceration, bleeding, or discharge. About 1% to 2% of men will have no symptoms [201,204]. In diagnosing male breast cancer, the primary consideration is to distinguish cancer from gynecomastia, which is present in about 30% of healthy men [202].
The approach to the diagnostic evaluation of male breast cancer is the same as for female breast cancer. A history and physical examination will help determine potential risk factors and identify the clinical features. Mammography has good sensitivity and specificity, and ultrasonography may be useful, especially for detecting involvement of the lymph nodes [202]. Biopsy is essential for elucidating the pathologic characteristics. In male breast cancers, the overexpression of estrogen receptor and progesterone receptors is likely [203,205].
As noted, data on male breast cancer are limited, and recommendations for treatment have been extrapolated from the literature on female breast cancer and from small series of men with the disease. Modified radical mastectomy is used most often, with lumpectomy rarely performed [203]. Sentinel node biopsy has also been effective in men [206,207]. Adjuvant radiation therapy has been associated with a lower local recurrence rate and a higher survival rate [202,203]. Adjuvant chemotherapy has been carried out according to guidelines for women at high risk for recurrence. Adjuvant hormone therapy has a clear role in the treatment of men with hormone receptor-positive cancer, with reductions in recurrence and death [204,208]. In addition, tamoxifen has led to a 50% response rate for metastatic breast cancer [202].
| A) | is best treated with behavioral therapy alone. | ||
| B) | is most common in men who are 60 years of age or older. | ||
| C) | can be treated with one of several FDA- approved medications. | ||
| D) | should not be diagnosed on the basis of the sexual history alone. |
The reported prevalence of premature ejaculation in the United States has varied widely, ranging from 5% to 40%, depending primarily on the definition [210,212]. The highest prevalence is found among men who are 60 years of age or older [214].
There are no established criteria for the diagnosis of premature ejaculation; clinicians should assess medical, relationship, and sexual history and perform a focused physical examination to make the diagnosis [354]. Laboratory studies or physiologic testing is needed only if the history or physical examination suggests a complex cause [212,354]. Among the details to be elicited from the history are [212]:
Frequency and duration of premature ejaculation
Relationship of premature ejaculation to specific partners
Degree of stimulus resulting in premature ejaculation
Nature and frequency of sexual activity (foreplay, masturbation, intercourse, use of visual cues)
Impact of premature ejaculation on sexual activity
Types and quality of personal relationships and quality of life
Aggravating or alleviating factors
Relationship to drug use or misuse
The patient's partner may be helpful in providing a description of the problem, and care should be taken to distinguish premature ejaculation from erectile dysfunction [212]. The AUA recommends that, for men with concomitant premature ejaculation and erectile dysfunction, erectile dysfunction should be treated first [212].
The treatment approaches for premature ejaculation include psychologic, behavioral, and pharmacologic therapies, and the risks and benefits of all options should be discussed with the patient and, when possible, his partner [212,354]. Behavioral therapy was once considered to be the standard therapy, but studies have shown that the best approach may involve a combination of therapies to address the limitations of each approach as well as the multimodal causes of premature ejaculation [210,217,218]. The 2022 AUA/Sexual Medicine Society of North America guideline recommends that, in addition to pharmacologic treatment, providers consider referring men with premature ejaculation to a mental health professional with expertise in sexual health [354].
No medication has been approved for the treatment of premature ejaculation, leaving the pharmacologic treatment to involve the off-label use of serotonin reuptake inhibitors or topical anesthetics that act by prolonging the latency of ejaculation [210,212,218,219,354]. The recommended first-line pharmacotherapeutic options are "on demand" clomipramine; a nonselective serotonin reuptake inhibitor; daily selective serotonin reuptake inhibitor (e.g., fluoxetine, paroxetine, sertraline); and topical penile anesthetics [212,354]. The doses studied have varied, and dosing is prescribed as either continuous (daily regimen) or situational (taken only before sexual activity); the optimal duration of therapy has not been determined (Table 10) [212,354]. The side effects of these drugs have not been evaluated outside the depression setting, but the effects appear to be similar for men who are not using the drug for depression, with the most common effects being nausea, dry mouth, and drowsiness [212].
| A) | Obesity | ||
| B) | Depression | ||
| C) | History of smoking | ||
| D) | Cardiovascular disease |
Erectile dysfunction has been reported to be more common among men with comorbidities; independent risk factors include age, diabetes, metabolic syndrome, cardiovascular disease, obesity, and sedentary lifestyle [214,234,235]. Among men with no known cardiovascular disease, erectile dysfunction has preceded coronary artery disease, stroke, and peripheral artery disease by an average of three years (range: two to five years) [236]. In addition, a meta-analysis (14 cohort studies; 92,757 men) showed that erectile dysfunction was an independent risk factor for cardiovascular and cerebrovascular events [237]. Other risk factors for erectile dysfunction include hormone disorders, neurologic conditions, psychologic disorders, history of surgery or radiation in the pelvic region, use of illicit drugs, and some prescription drugs (most notably, antihypertension agents) [238]. Encouraging men with these risk factors to modify their lifestyle and/or treating comorbidities may help reduce the risk of erectile dysfunction [239].
| A) | serum half-life. | ||
| B) | side effect profile. | ||
| C) | duration of action. | ||
| D) | time to maximum serum level. |
After treatment of erectile dysfunction is initiated, referral to a mental health professional should be considered to promote treatment adherence, reduce performance anxiety, and integrate therapies into a sexual relationship [355]. Both the AUA and the ACP recommend oral phosphodiesterase-5 inhibitors as first-line pharmacotherapy for erectile dysfunction in men for whom this class of drugs is not contraindicated [230,231,355]. Four drugs in the class have been approved for use in the treatment of erectile dysfunction: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra, Spedra). Sildenafil and vardenafil differ from tadalafil with respect to the time to maximum serum level (1 hour vs. 2 hours) and serum half-life (4 hours vs. 18 hours) [230]. Furthermore, the duration of action is longest for tadalafil (up to 36 hours) [240]. The inhibitory effect of these drugs causes vascular smooth muscle relaxation in the corpus cavernosum, resulting in increased erection hardness and prolonged duration in men with erectile dysfunction who have sufficient intact vasculature [355].
Data from multiple trials and systematic reviews have demonstrated similar efficacy for phosphodiesterase-5 inhibitors in treating erectile dysfunction, particularly for sildenafil, tadalafil, and vardenafil [355]. Each of these drugs substantially improves erectile function and successful sexual intercourse compared with placebo [231]. Relative efficacy is less clear for avanafil because published comparative studies are limited. The ACP notes that there is insufficient evidence for recommending one drug over another and suggests that the choice be made according to the preferences of an individual patient with respect to ease of use, cost, and the adverse effects profile [231]. One systematic review and meta-analysis found evidence that tadalafil is the most effective agent, followed by vardenafil, with no major differences in the safety profile of any of the phosphodiesterase-5 inhibitors [241].
The side effects of all four drugs are similar, with headache, dyspepsia, facial flushing, nasal congestion, and visual disturbances being the most common events [230,240,242]. The FDA has issued two mandates to revise labeling of these agents. In 2005, the agency required labels for sildenafil, tadalafil, and vardenafil to reflect the possibility of sudden vision loss after taking the drugs for a period of time [243]. The alert was associated with several case reports suggesting a temporal association between use of one of the drugs and nonarteritic anterior ischemic optical neuropathy (NAION), a rare disorder characterized by sudden loss of vision in one eye [243,355]. However, subsequent studies showed that the risk of NAION was similar among men who were and were not taking a phosphodiesterase-5 inhibitor [244,245]. Risk factors for spontaneous NAION include older age, White race, small optic discs with low cup-to-disc ratio, and vascular disease, leading some investigators to suggest an examination of the fundus be performed on men who may be at higher risk for NAION before a phosphodiesterase-5 inhibitor is prescribed [243].
| A) | amyl nitrite. | ||
| B) | nitroglycerin. | ||
| C) | an alpha blocker. | ||
| D) | Any of the above |
Use of a phosphodiesterase-5 inhibitor is contraindicated in several situations. They should not be taken by men who take organic nitrates (nitroglycerin) or nitrites (amyl nitrite) [248,249]. Vardenafil should not be used for men with a history of prolonged QT interval (or who take medication to prolong the QT interval) [230]. The use of a phosphodiesterase-5 inhibitor concomitantly with an alpha-blocker for lower urinary tract symptoms may lead to increased systemic vasodilation and hypotension [230].
| A) | equivalent to menopause in women. | ||
| B) | well defined by a level of testosterone. | ||
| C) | similar to hypogonadism in younger male individuals. | ||
| D) | associated with a loss of sexual satisfaction and overall well-being. |
In both men and women, levels of sex hormones decline with age. However, the ways in which these levels change and the symptoms associated with the decline differ greatly between men and women. There is no well-defined equivalent of menopause in men, although the phrase "andropause" is used frequently to refer to decreased testosterone and resulting symptoms. Other phrases, most notably androgen deficiency syndrome and late-onset hypogonadism, may be more accurate descriptors of the process. By any name, the condition is a complex of symptoms that includes loss of sexual satisfaction and overall well-being [251]. The condition is related to lower testosterone levels, which begin to decrease 1% to 2% each year beginning at 30 years of age [252].
Late-onset hypogonadism is distinct from hypogonadism in younger male individuals. For boys and young men, hypogonadism is related to testicular failure and is usually associated with a congenital abnormality, most often Klinefelter syndrome [251]. In older men with hypogonadism, testosterone levels are rarely as low as the levels in young men with primary hypogonadism [251].
Several important questions about late-onset hypogonadism remain unanswered [252,253]:
It is unclear whether the symptoms are caused by a reduction in testosterone or are a result of the normal physiologic process of aging.
There is no consistent level of testosterone to define hypogonadism, and there is confusion about what testosterone levels should be measured.
There is ongoing debate about the risk-benefit ratio of testosterone therapy for older men.
| A) | All men should be screened for androgen deficiency. | ||
| B) | A diagnostic testosterone level can be determined at any time of day. | ||
| C) | Testosterone therapy should not be used for men with a hematocrit of more than 40%. | ||
| D) | Men receiving testosterone therapy should be monitored three to six months after initiation of treatment and then annually. |
RECOMMENDATIONS OF THE ENDOCRINE SOCIETY REGARDING TESTOSTERONE THERAPY FOR ADULT MEN WITH HYPOGONADISM
| Diagnosis and evaluation |
| ||||||||||
| Treatment |
| ||||||||||
| Monitoring |
| ||||||||||
| Screening |
|
| A) | is correctable in most cases. | ||
| B) | is not affected by prescription medications. | ||
| C) | is the only cause in most cases of infertile couples. | ||
| D) | affects men younger than 25 years of age twice as often as older men. |
Infertility is clinically defined as the inability to conceive after one year of unprotected intercourse [264]. Approximately 15% of couples are unable to conceive after one year of unprotected intercourse. A male factor is the only cause in approximately 20% of infertile couples and is a contributing factor in another 20% to 40% [264]. Fertility declines with age, and research has shown that men older than 35 years of age are twice as likely to be infertile as men younger than 25 years of age [265,266]. Approximately 15% of infertile men have azoospermia, the complete absence of sperm in the ejaculate [267].
More than half of male infertility or subfertility is potentially correctable; often, the cause is unknown. The causes, both correctable and uncorrectable, include [264,268]:
Varicocele
Obstruction of a duct (epididymal, vasal, or ejaculatory)
Ejaculatory dysfunction
Testicular atrophy
Hypogonadotropic hypogonadism
Infection
Side effects of medication
Environmental toxins
Bilateral cryptorchidism
Genetic abnormality (Y chromosome microdeletion)
Congenital absence of vas deferens
| A) | Men at increased risk should be routinely screened for chlamydia. | ||
| B) | Men at low risk for gonorrhea should be screened every three to five years. | ||
| C) | Screening for herpes simplex virus type 2 should be done for asymptomatic men. | ||
| D) | Young male individuals (13 to 26 years of age) should receive the HPV vaccine if they have not already. |
Recommendations for screening vary according to risk and the type of STI (Table 15) [284]. The USPSTF also recommends high-intensity behavioral counseling for all sexually active adolescents and for adults at increased risk for STIs and HIV [284]. The USPSTF has not issued recommendations for screening for HPV, but beginning in 2011, the Advisory Committee on Immunization Practices (ACIP) recommended HPV vaccination for male individuals [276]. The ACIP recommends routine use of quadrivalent HPV vaccine for boys 11 or 12 years of age and for male individuals 13 to 26 years of age who have not initiated or completed the three-dose series [276,286]. The ACIP also notes that men 27 to 45 years of age may also be vaccinated if at high risk, as determined through shared decision-making [276,285,286]. In addition, hepatitis B vaccination is recommended for any patient who is being evaluated for an STI [173].
U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS FOR SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS (STIs) IN MALE INDIVIDUALS
| STI | Recommendation |
|---|---|
| Chlamydia and gonorrhea | Insufficient evidence to recommend for or against screening in men |
| Syphilis | Strongly recommend screening for individuals at increased risk |
| Genital herpes | No screening for asymptomatic adults and adolescents |
| A) | chlamydia. | ||
| B) | hepatitis B. | ||
| C) | herpes simplex virus 2. | ||
| D) | human papillomavirus. |
The CDC recommends that all individuals who are evaluated for gonorrhea should also be evaluated for chlamydia, syphilis, and HIV infection [173]. In one study of more than 3,800 men and women, approximately 10% to 30% of individuals with gonorrhea had concomitant infection with chlamydia [290]. The typical lesions of genital HSV-2 in men appear on or around the penis and are first noted as either a single or multiple erythematosus macular lesion(s). However, these lesions are absent in many infected individuals [173]. Viral culture is the preferred test for the diagnosis of HSV-2, but it requires two to seven days for results. The sensitivity of viral culture depends on the quality of the sample and the time at which the sample is obtained; sensitivity declines as the lesion begins to heal. A PCR test is available and is suggested by the CDC for analysis of cerebrospinal fluid when central nervous system disease is suspected [173]. Type-specific serologic tests are available as laboratory assays and point-of-care tests [173]. These tests have varying degrees of sensitivity for the detection of the HSV-2 antibody (80% to 90%) and specificity of at least 96% [173].
| A) | Acyclovir | ||
| B) | Benzathine penicillin | ||
| C) | Ceftriaxone and doxycycline | ||
| D) | Azithromycin and penicillin G |
TREATMENT OF CHLAMYDIA, SYPHILIS, AND GONORRHEA AS RECOMMENDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION
| Infection | Recommended Treatment | Notes | |||||
|---|---|---|---|---|---|---|---|
| Chlamydia |
| A meta-analysis showed treatment failure among men was higher for azithromycin than for doxycycline. | |||||
| Gonorrhea |
|
| |||||
| Primary and secondary syphilis | Benzathine penicillin G 2.4 million units IM (single dose) |
|
| A) | High-risk patients should be assessed yearly. | ||
| B) | Annual HIV screening should not be considered for low-risk men. | ||
| C) | Hepatitis A and B immunization should be assessed in high-risk patients only. | ||
| D) | Anal NAAT should be considered for men who have receptive anal intercourse. |
| A) | The misuse of illicit drugs is expected to decrease as the general population ages. | ||
| B) | The rate of alcohol misuse is higher among younger women than among younger men. | ||
| C) | Men are less likely than women to have psychosocial problems related to substance misuse. | ||
| D) | Men older than 65 years are much more likely to be "problem" drinkers than women in that age group. |
As noted, substance misuse is higher among men than among women in all age categories, and men are more likely to have psychosocial problems related to the misuse [28,307]. Although the rate of alcohol misuse is highest among younger men, men older than 65 years of age are of special concern because they are much more likely than women to be "problem" drinkers and to misuse a wide range of illicit as well as prescription drugs [307]. As the general population ages, the misuse of illicit drugs is expected to increase [314]. Adding to this problem is the low rate of screening for alcohol misuse in the older population and the secrecy of many men about drug use [314,315].
| A) | CAGE questionnaire. | ||
| B) | Michigan Alcohol Screening Test. | ||
| C) | Alcohol-Related Problems Survey. | ||
| D) | Alcohol Use Disorders Identification Test. |
Several professional organizations, including the USPSTF, recommend screening and behavioral counseling intervention to reduce alcohol misuse [318]. However, reported rates of screening have been low [319]. Several screening instruments have been developed, and they vary in the number of questions, the populations for which they are best suited, and their usefulness in specific situations; no one tool is perfect [320,321,322,323]. The CAGE questionnaire, which includes four questions, is best for detecting alcohol dependency and is easy and quick to perform [320,321]. However, the test may not detect low, but risky, levels of drinking [307,324]. The Alcohol Use Disorders Identification Test (AUDIT) is the most accurate for detecting problem drinking [319,322].
| A) | pharmacologic therapy alone. | ||
| B) | cognitive behavioral therapy alone. | ||
| C) | interpersonal psychotherapy alone. | ||
| D) | psychotherapy and pharmacologic therapy. |
The treatment approach will depend on the severity of symptoms and the patient's preference. In general, a combination of psychotherapy and pharmacologic management provides the best results for most men [328,335]. Potential psychotherapy approaches include cognitive behavior therapy and interpersonal psychotherapy [300,307,328]. First-line pharmacologic treatment involves the use of selective serotonin reuptake inhibitors, such as paroxetine, sertraline, and fluoxetine [307]. This treatment approach has efficacy rates of 30% to 70% [328]. Clinicians should emphasize the importance of taking the medication as prescribed, as it may be two to four weeks before a benefit is evident [328]. Depression that is associated with chronic illness is often seen as an inevitable consequence of the disease, but the depression should be treated. Frequently, the treatment improves the overall outcome [335].
| A) | Health fairs | ||
| B) | Support groups | ||
| C) | Short video clips | ||
| D) | Pamphlets emphasizing the importance of prevention |
As a result of men's reluctance to seek help, educational strategies that provide anonymity may be particularly well-suited for them [45,339]. Print resources should be distributed through a variety of venues that men frequent, such as the workplace, schools, religious organizations, sports arenas, men's organizations or clubs, pubs, supermarkets, car and motorbike dealerships, and barbershops [45,339,340]. In addition, digital media may be effective, especially for younger men. A study showed that 90-second educational video clips on men's health, sent by e-mail, were well-received [341].
| A) | Lipid profile | ||
| B) | Visual acuity | ||
| C) | Cancer-related check-up | ||
| D) | Abdominal aortic aneurysm |
RECOMMENDATIONS AND SUGGESTIONS FOR HEALTH ASSESSMENTS, SCREENING, AND COUNSELING FOR MEN
| Intervention | Suggested Frequency | Relevant Ages (Years) | Recommending Body/Source | ||
|---|---|---|---|---|---|
| Routine physical examination (with determination of height, weight, and body mass index) | Every 3 to 5 years | 18 to 39 | — | ||
| Every 1 to 2 years | 40 to 49 | ||||
| Yearly | 50 and older | ||||
| Blood pressure screening | Every 1 to 2 years, depending on blood pressure | Beginning at 18 | USPSTF | ||
| Cholesterol level/lipid profile | At least every 5 years | 40 to 75 (earlier if at increased risk) | USPSTF | ||
| Diabetes (type 2) and prediabetes screening | Every 3 years | 35 to 70 in men with overweight or obesity | USPSTF | ||
| Cancer-related check-up (for cancer of the thyroid, testicles, lymph nodes, oral cavity, and skin) | At each routine examination | Beginning at 20 | ACS | ||
| Assessment, Counseling, and Behavioral Interventions as Appropriate | |||||
| Tobacco use | At each routine examination | All men | USPSTF | ||
| Alcohol use | At each routine examination | All men | USPSTF | ||
| Drug (illicit) use | At each routine examination | All men | ASAM | ||
| Depression | At each routine examination, when staff-assisted depression care supports are in place | All men | USPSTF | ||
| Counseling | |||||
| Healthy diet | At each routine examination | Men with risk factors for cardiovascular disease and diet-related chronic diseases | USPSTF | ||
| Exercise | At each routine examination | All men | AAFP, AMA, AHA, CDC | ||
| Sun avoidance and use of sunscreen | At each routine examination | All men | ACS, AAD, NIH Consensus Panel | ||
| Skin examination for melanoma | At each routine examination | All men | ACS | ||
| Avoidance of sexually transmitted infections | At each routine examination | All sexually active men at increased risk | CDC | ||
| Risk of HIV infection | At each routine examination | All men who have sex with men | AAFP | ||
| Risk for hepatitis A and B | At each routine examination | All men who have sex with men and others at high risk | AAFP | ||
| Sexual health | At each routine examination | All men | AAFP | ||
| Screening | |||||
| Colorectal cancer | Every 1 to 10 years, depending on risk and test used | 45 to 75 | USPSTF | ||
| Osteoporosis | At each routine examination | By 65 | ACP | ||
| HIV | Not established (encourage men to be tested) | 15 to 65 (younger and older men at increased risk) | USPSTF | ||
| Visual acuity (comprehensive eye examination) | Yearly | Beginning at 65 | AAO | ||
| Abdominal aortic aneurysm (ultrasonography) | Once | 65 to 75 (men who have ever smoked) | USPSTF | ||
| Immunizations | |||||
| Tetanus, diphtheria, pertussis (Td/Tdap) | Once (Tdap), with booster (Td or Tdap) every 10 years | All men | ACIP | ||
| Influenza vaccine | Yearly | All men | ACIP | ||
| Pneumococcal vaccine | Once | 65 and older (19 to 64 if risk) (one or two doses, depending on vaccine) | ACIP | ||
| Hepatitis A | Once | All men, if risk factors are present (2 or 3 doses, depending on vaccine) | ACIP | ||
| Hepatitis B | Once | 19 to 59, and 60 and older if risk factors are present (2, 3, or 4 doses, depending on vaccine or condition) | ACIP | ||
| Human papillomavirus (HPV) | Once |
| ACIP | ||
| Zoster (shingles) | Once | 50 and older or younger if risk factors present (2 doses) | ACIP | ||
| Haemophilus influenzae type b (Hib) | Once | All men, if risk factors present (1 or 3 doses depending on indication) | ACIP | ||
| Meningococcal A, C, W, Y | Once | All men, if risk factors present (1 or 2 doses depending on indication) | ACIP | ||
| Meningococcal B | Once | All men, if risk factors present (2 or 3 doses depending on vaccine and indication) | ACIP | ||
